Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
$21.46
-$0.14(-1.13%)
At close: 4:00 PM EST
$21.46
-$0.14(-1.13%)
Day’s Range― - ―
52-Week Range$5.64 - $21.49
Previous CloseN/A
Volume175.11K
Average Volume (3M)6.08M
Market Cap
$2.22B
Enterprise Value$2.02B
Total Cash (Recent Filing)$441.11M
Total Debt (Recent Filing)$2.79M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
May 13, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding103,297,690
10 Day Avg. Volume1,135,782
30 Day Avg. Volume6,082,853
Financial Highlights & Ratios
PEG Ratio-4.58
Price to Book (P/B)2.18
Price to Sales (P/S)6.09
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue12.79
Enterprise Value/Gross Profit14.35
Enterprise Value/Ebitda-19.11
Forecast
1Y Price Target
$20.86Price Target Upside-2.80% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$240.45M
Bulls Say, Bears Say
Bulls Say
Acquisition OfferAll-cash acquisition offer from Servier gives shareholders a clear exit at a sizable premium, delivering a definite value outcome for investors.
Commercial PerformanceRobust Ojemda launch in pediatric brain tumor patients, combined with durable patient persistence and growing physician adoption, underpins continued revenue expansion and higher commercial confidence.
Pipeline Clinical ReadoutsUpcoming early-stage clinical readouts for a B7-H4 antibody–drug candidate and an Emi-Le update could materially increase pipeline value and clarify advancement plans if results are positive.
Bears Say
Clinical Timing And Profitability PressureKey clinical trial readouts scheduled after the anticipated deal close reduce near-term catalysts, while elevated operating expenses heighten reliance on sustained revenue growth to reach profitability.
Transaction Completion RisksRegulatory approval, shareholder support and competing bids remain uncertain, and potential closing delays or integration disruption could create significant near-term downside risk.
Valuation And Analyst ActionsAnalyst downgrades and price targets tied to the cash offer anchor the company's valuation to the transaction price, limiting upside from standalone growth expectations.
Day One Biopharmaceuticals News
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $21.49 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $2.22B.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 27 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Feb 24, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.061.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Overvalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.28.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 103,297,690 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went down -9.068%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Day One Biopharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.86 (-2.80% Downside)
$20.86 (-2.80% Downside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 859.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
201.82%
12-Months-Change
Fundamentals
Return on Equity
-23.43%
Trailing 12-Months
Asset Growth
-12.86%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Company Deck
DAWN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum for Ojemda with exceptional revenue growth (FY2025 revenue up 172% YoY; Q4 sequential growth of 37%), robust prescription trends (>4,600 scripts, +180% YoY) and a solid balance sheet (~$441M cash, no debt). Clinical readouts (FIREFLY-1 three-year data) provide compelling efficacy and long TTNT supporting clinical value, and the Mersana acquisition adds a promising near-term pipeline asset (EMILY) with mid-2026 data expected. Offsetting risks include pediatric safety considerations (decreased growth velocity, anemia, occasional severe rash), concentration on a single marketed product, expected gross-to-net pressure in 2026 (guidance rising to 16%–19%), and timing/regulatory uncertainties for pipeline readouts (FIREFLY-2 top-line mid-2027, EMILY data mid-2026). Overall the positives — strong commercial execution, clear growth guidance, healthy payer coverage, and a strong cash position — outweigh the challenges, though pipeline timing and safety management remain important watchpoints.View all DAWN earnings summariesDAWN Stock 12 Month Forecast
Average Price Target
$20.86
▼(-2.80% Downside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Septerna, Inc.
―
Ownership Overview
2.29% Insiders
17.09% Mutual Funds
25.92% Other Institutional Investors
41.81% Public Companies and
Individual Investors